Suraksha Diagnostic is an integrated diagnostic provider in Eastern India, operating a hub-and-spoke network of 72 centers as of Q1 FY27, with a revenue mix of pathology (48.85%), radiology (44.26%), and doctor consultancy (6.89%) in FY26. The company serves a fragmented market dominated by mom-and-pop players, positioning itself as the largest organized player in the region. Its mature centers (over two years old) delivered a 40.9% EBITDA margin in Q1 FY27, while the overall blended margin was 36%, indicating that scale drives profitability. Revenue per patient stood at INR2,321 and EBITDA per patient at INR835 in Q1 FY27, reflecting a high-value test mix that does not rely on price increases but on clinical mix shift.
The economics persist because of local brand equity and a referral engine from in-house doctor consultations that funnel into diagnostics. The company operates the only commercial genomics lab in Eastern India, with the GeneXus NGS platform that reduces turnaround times for genomic tests from 14-17 days to 48 hours, creating a significant switching cost for referring physicians. Its hub-and-spoke model, backed by 214 franchisee-owned collection centers, allows capital-efficient expansion into underserved districts. Cost advantages come from centralized procurement, including a renegotiated deal with Roche for biochemistry reagents, and a reference lab with 2.5 times current test volume capacity, providing inherent operating leverage that does not require additional capex to absorb volume growth.
Over the next 18-24 months, Suraksha is executing an aggressive expansion from 72 centers to 100 by FY28, with FY27 capex of INR70-80 crores funding five hubs and eight spokes, including entry into Bihar, Tripura, and Jharkhand. Management guides FY27 revenue growth of 15% and an EBITDA margin not below 34%, with Q1 FY27 already at 36% and mature centers at 40.9%. By mid-2028, the centers opened in FY27 will have matured past their 5-6 month (small) and 9-12 month (hub) breakeven points, lifting the blended margin toward the medium-term target of 35% and eventually 38-39% long term. The genomics vertical, which grew 136% YoY to INR13.7 million in Q1 FY27, is targeting ~20% quarterly growth and is expected to reach a INR4+ crore annual run rate by FY27, with further scaling into whole genome testing, AI-driven diagnostics, and an HRD assay for ovarian cancer.
Management has a mixed record on delivery: for FY26, they guided 15% revenue growth and 33-34% EBITDA margin, but actual revenue grew 22% while the EBITDA margin ended at 31.73%, forcing a mid-year guidance cut. For FY27, they have guided 15% revenue growth and a 33% EBITDA margin, but in the Aug 2026 call they raised the commitment to not below 34% for the full year, with Q1 delivering 36%. They have consistently committed to 100 centers by FY28 and have opened 3 hubs and 6 spokes in the first quarter of FY27, on track. The balance sheet remains net cash positive at around INR29 crores, funding the INR70-80 crore capex without dilution, and the company has not changed its capital allocation stance, with no equity raising or dividend initiation yet.
The quantified path: FY26 EBITDA was approximately INR985 million; at 15% revenue growth and 34% EBITDA margin, FY27 EBITDA would be around INR1.21 billion, rising to roughly INR1.39 billion in FY28 at 35% margin. This assumes mature centers sustain ~12.5% growth (Q1 FY27 actual) and new centers ramp without prolonged pre-operative losses. The single most important watchpoint is the pace of margin recovery: the FY26 miss was due to new center costs, but Q1 FY27 shows new centers turning profitable at a 6.5% EBITDA margin after being negative 5.5% in the prior quarter, resolving the tension as operational rather than structural. The falsifier would be if expansion into Bihar, Tripura, and Jharkhand faces licensing or demand setbacks, or if cannibalization from new spokes (5-10% potential) outweighs volume gains, causing blended margins to stay below 34% for FY27.
companyname: Suraksha Diagnostic Limited ticker: SURAKSHA sector: Healthcare / Diagnostics Suraksha Diagnostic Limited is an integrated diagnostic company operating across Eastern India, headquartered in Kolkata. Founded in 1992 by Dr. Somnath Chatterjee and Late Kishan Kumar Kejriwal, it offers pathology testing, radiology imaging, and medical consultations under one roof. The company listed on BSE and NSE on 06 December 2024 through an Offer For Sale. The operating model is a hub-and-spoke n...
Read the full report →capex, margin expansion, new product segment, geographic expansion
FY27 revenue growth guided at 15% driven by expansion into Bihar, Tripura, and Jharkhand, and scaling of new centers
Guidance maintainedmixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Suraksha Diagnostic Ltd. and 4,900+ companies.
5-day free pass. No card required.